Clinical Trials ProgressThe Phase 3 ACTION study for ONC201 is progressing, with an increasing number of study sites and patient enrollment expected to accelerate.
Financial StabilityChimerix reported better-than-expected 4Q23 earnings per share, surpassing analyst estimates and demonstrating financial stability with a substantial cash reserve.
Regulatory MilestonesONC201 has received Fast Track Designation and Rare Pediatric Disease Designation from the FDA, indicating regulatory support and potential for expedited development.